Abiomed Inc. (ABMD) News

Abiomed Inc. (ABMD): $258.47

4.68 (+1.84%)

POWR Rating

Component Grades













Filter ABMD News Items

ABMD News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ABMD News Highlights

  • For ABMD, its 30 day story count is now at 21.
  • Over the past 22 days, the trend for ABMD's stories per day has been choppy and unclear. It has oscillated between 1 and 16.
  • The most mentioned tickers in articles about ABMD are DECK, LI and LU.

Latest ABMD News From Around the Web

Below are the latest news stories about Abiomed Inc that investors may wish to consider to help them evaluate ABMD as an investment opportunity.

Riding The Stock Waves: Update On The Medical Devices Sector

For the Stock Waves webinar on February 10, we wanted to focus on medical devices sector using the iShares U.S. Medical Devices ETF (IHI). IHI is looking pretty convincing so far with this bounce off of the January low that a bottom has been struck. That low was the 38.2%...

Stock Waves on Seeking Alpha | February 21, 2022

Here's Why You Should Retain Abiomed (ABMD) Stock For Now

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

Yahoo | February 11, 2022

Abiomed to Present at the SVB Leerink 11th Annual Global Healthcare Conference

DANVERS, Mass., February 08, 2022--Abiomed to present at the SVB Leerink 11th Annual Global Healthcare conference.

Yahoo | February 8, 2022

Abiomed Inc. (ABMD) CEO Mike Minogue on Q3 2022 Results - Earnings Call Transcript

Abiomed, Inc. (ABMD) Q3 2022 Earnings Conference Call February 03, 2022, 08:00 AM ET Company Participants Nicole Nath - Manager, Investor Relations Mike Minogue - Chairman, President and Chief Executive Officer Todd Trapp - Vice President and Chief Financial Officer Conference Call Participants Chris Cooley - Stephens Chris Pasquale -...

SA Transcripts on Seeking Alpha | February 4, 2022

Abiomed Non-GAAP EPS of $1.13 beats by $0.16, revenue of $261.18M beats by $9.71M

Abiomed press release (NASDAQ:ABMD): Q3 Non-GAAP EPS of $1.13 beats by $0.16. Revenue of $261.18M (+12.7% Y/Y) beats by $9.71M. The company is increasing the lower end of its fiscal year 2022 revenue guidance to a range of $1,025 million to $1,030 million with growth of 21% - 22% versus...

Seeking Alpha | February 3, 2022

Abiomed, Inc. 2022 Q3 - Results - Earnings Call Presentation

The following slide deck was published by Abiomed, Inc. in conjunction with their 2022 Q3 earnings call....

SA Transcripts on Seeking Alpha | February 3, 2022

BTIG Reaffirms Their Hold Rating on Abiomed (ABMD)

E ratio of 94.72.

Howard Kim on TipRanks | February 3, 2022

Abiomed (ABMD) Beats on Q3 Earnings, Narrows FY22 Guidance

Abiomed's (ABMD) strength in Impella product revenues drives its Q3 top line.

Yahoo | February 3, 2022

Abiomed (ABMD) Q3 Earnings and Revenues Top Estimates

Abiomed (ABMD) delivered earnings and revenue surprises of 15.31% and 3.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 3, 2022

Abiomed Announces Record Revenue of $261 Million, up 13% Year Over Year

DANVERS, Mass., February 03, 2022--Abiomed announces record revenue of $261 million, up 13% year over year. Increases low end of guidance: $1,025 Million - $1,030 Million, up 21% - 22%.

Yahoo | February 3, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.5529 seconds.